Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Krystal Biotech Inc
KRYSCurrent price
168.57 USD
+3.68 USD (+2.23%)
Last closed
166.01 USD
Company
www.krystalbio.com
ISIN
US5011471027
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
4 871 403 520 USD
Yield for 12 month
+7.20 %
1Y
3Y
5Y
10Y
15Y
KRYS
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania. Address: 2100 Wharton Street, Pittsburgh, PA, United States, 15203
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
215.20 USDP/E ratio
56.19Dividend Yield
–Current Year
+290 515 000 USD
Last Year
+50 699 000 USD
Current Quarter
+91 139 000 USD
Last Quarter
+83 841 000 USD
Current Year
+270 454 000 USD
Last Year
+47 605 000 USD
Current Quarter
+86 190 000 USD
Last Quarter
+77 157 000 USD
Key Figures KRYS
1 year
3 years
5 years
10 years
EBITDA
105 662 000 USD
Operating Margin TTM
Price to Earnings
56.19
Return On Assets TTM
6.88 %
PEG Ratio
–
Return On Equity TTM
10.34 %
Wall Street Target Price
215.20 USD
Revenue TTM
290 515 008 USD
Book Value
32.87 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
116.30 %
Dividend Yield
–
Gross Profit TTM
270 454 016 USD
Earnings per share
3.00 USD
Diluted Eps TTM
3.00 USD
Most Recent Quarter
IV 2024
Quarterly Earnings Growth YOY
409.50 %
Profit Margin
30.69 %
Dividend Analytics KRYS
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History KRYS
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Stock Valuation KRYS
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
56.19
Forward PE
22.42
Enterprise Value Revenue
14.74
Price Sales TTM
16.77
Enterprise Value EBITDA
38.95
Price Book MRQ
5.15
Financials KRYS
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators KRYS
For 52 weeks
141.72 USD
219.34 USD
50 Day MA
174.53 USD
Shares Short Prior Month
2 701 192
200 Day MA
178.99 USD
Short Ratio
10.13
Shares Short
2 711 754
Short Percent
15.74 %
BeatStart